XML 49 R32.htm IDEA: XBRL DOCUMENT v3.23.1

Corporate and Company information (Tables)

12 Months Ended

Dec. 31, 2022

Corporate and Company information

Schedule of percentage of equity interest in subsidiary

​

​	​	​	​	​	​	​	​	​	​
​	​	​	​	​	​	% of equity interest			​
Name		Legal seat		Country of incorporation		2022		2021	​
Lava Therapeutics N.V.	​	Utrecht	​	The Netherlands	​	100	%	100	%
Lava Therapeutics Inc.	​	Delaware	​	United States of America	​	100	%	100	%

​

X

- Definition

The disclosure of information about consolidated structured entities. [Refer: Consolidated structured entities [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2022-03-24
-Section Nature of the risks associated with an entity's interests in consolidated structured entities
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS12_g14-17__IFRS12_g14-17_TI
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_DisclosureOfInformationAboutConsolidatedStructuredEntitiesExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	lvtx_CorporateInformationAbstract
Namespace Prefix:	lvtx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration